• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

光化性角化病的现行疗法。

Current therapies for actinic keratosis.

机构信息

Department of Plastic, Reconstructive and Cosmetic Surgery, Campus Bio-Medico University Hospital, Rome, Italy.

Department of Dermatology, Maggiore Hospital, University of Trieste, Trieste, Italy.

出版信息

Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3.

DOI:10.1111/ijd.14767
PMID:32012240
Abstract

Actinic keratosis (AK) is a very common skin disease caused by chronic sun damage, which in 75% of cases arises on chronically sun-exposed areas, such as face, scalp, neck, hands, and forearms. AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC. For this reason, all AK should be treated, and clinical follow-up is recommended. The aims of treatment are: (i) to clinically eradicate evident and subclinical lesions, (ii) to prevent their evolution into SCC, and (iii) to reduce the number of relapses. Among available treatments, it is possible to distinguish lesion-directed therapies and field-directed therapies. Lesion-directed treatments include: (i) cryotherapy; (ii) laser therapy; (iii) surgery; and (iv) curettage. Whereas, field-directed treatments are: (i) 5-fluorouracil (5-FU); (ii) diclofenac 3% gel; (iii) chemical peeling; (iv) imiquimod; and (v) photodynamic therapy (PDT). Prevention plays an important role in the treatment of AKs, and it is based on the continuous use of sunscreen and protective clothing. This review shows different types of available treatments and describes the characteristics and benefits of each medication, underlining the best choice.

摘要

光化性角化病(AK)是一种由慢性太阳损伤引起的常见皮肤病,在 75%的病例中,这种病发生在长期暴露于太阳的部位,如面部、头皮、颈部、手部和前臂。由于其可能进展为侵袭性鳞状细胞癌(SCC),因此 AK 必须被视为早期 SCC。出于这个原因,所有的 AK 都应该治疗,并建议进行临床随访。治疗的目的是:(i)临床根除明显和亚临床病变,(ii)预防其演变为 SCC,(iii)减少复发次数。在现有的治疗方法中,可以区分病变定向治疗和区域定向治疗。病变定向治疗包括:(i)冷冻疗法;(ii)激光疗法;(iii)手术;和(iv)刮除术。而区域定向治疗是:(i)5-氟尿嘧啶(5-FU);(ii)双氯芬酸 3%凝胶;(iii)化学换肤;(iv)咪喹莫特;和(v)光动力疗法(PDT)。预防在 AK 的治疗中起着重要作用,它基于防晒霜和防护服的持续使用。本综述展示了不同类型的现有治疗方法,并描述了每种药物的特点和益处,强调了最佳选择。

相似文献

1
Current therapies for actinic keratosis.光化性角化病的现行疗法。
Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3.
2
Pharmacotherapy of actinic keratosis: an update.光化性角化病的药物治疗:更新。
Expert Opin Pharmacother. 2012 Sep;13(13):1847-71. doi: 10.1517/14656566.2012.716039.
3
Current management of actinic keratoses.光化性角化病的当前治疗方法。
Skin Therapy Lett. 2010 May;15(5):5-7.
4
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms.光化性角化病:用肿瘤异质性理论协调治疗模式。
J Invest Dermatol. 2021 Apr;141(4):727-731. doi: 10.1016/j.jid.2020.09.002. Epub 2020 Sep 18.
5
Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach.优化光化性角化病和光损伤皮肤的管理:采用逐步方法。
Cutis. 2009 Sep;84(3):169-75.
6
Local interventions for actinic keratosis in organ transplant recipients: a systematic review.光化性角化病在器官移植受者中的局部治疗:系统评价。
Br J Dermatol. 2019 Jan;180(1):43-50. doi: 10.1111/bjd.17148. Epub 2018 Oct 31.
7
What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: Commonly used field-directed and lesion-directed therapies.光动力疗法在治疗光化性角化病中起什么作用?第2部分:常用的光动力疗法和皮损靶向疗法。
Cutis. 2012 Jun;89(6):294-301.
8
Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.光化性角化病:光动力疗法、冷冻疗法、5-氟尿嘧啶、咪喹莫特、双氯芬酸,还是其他方法?事实与争议。
Clin Dermatol. 2013 Nov-Dec;31(6):712-7. doi: 10.1016/j.clindermatol.2013.05.007.
9
Ingenol Mebutate and the Treatment of Actinic Keratosis.没食子酸酯和光化性角化病的治疗。
J Drugs Dermatol. 2021 Jan 1;20(1):102-104. doi: 10.36849/JDD.5328.
10
Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.意大利医生对光化性角化病管理的意见和临床实践模式。
G Ital Dermatol Venereol. 2014 Apr;149(2):185-92.

引用本文的文献

1
CD93: A Promising NETs-Related Biomarker for Diagnosis and Therapy in Actinic Keratosis.CD93:一种用于光化性角化病诊断和治疗的有前景的与中性粒细胞胞外陷阱相关的生物标志物。
Onco Targets Ther. 2025 Aug 27;18:935-951. doi: 10.2147/OTT.S539790. eCollection 2025.
2
Descending the Reconstruction Ladder: Single-Stage Full-Thickness Skin Grafting for Wide Nasal Skin Malignant Defects.重建阶梯下行:单阶段全厚皮片移植修复广泛鼻皮肤恶性缺损
Indian J Plast Surg. 2025 Feb 24;58(4):259-268. doi: 10.1055/s-0044-1801836. eCollection 2025 Aug.
3
Experiences of Individuals with Cutaneous Leishmaniasis Receiving Intralesional Sodium Stibogluconate or Liquid Nitrogen Cryotherapy in Addis Ababa, Ethiopia-A Cross-Sectional Study.
埃塞俄比亚亚的斯亚贝巴接受病灶内注射葡糖酸锑钠或液氮冷冻疗法的皮肤利什曼病患者的经历——一项横断面研究
Trop Med Infect Dis. 2025 Jul 23;10(8):203. doi: 10.3390/tropicalmed10080203.
4
Actinic keratosis: comprehensive review of current treatments and emerging therapeutic innovations.光化性角化病:当前治疗方法及新兴治疗创新的全面综述
Postepy Dermatol Alergol. 2025 Jan 31;42(3):221-231. doi: 10.5114/ada.2024.147331. eCollection 2025 Jun.
5
Targeting Biomarkers of Proliferation and Inflammation (Ki67, p53, and COX-2) in Actinic Keratoses with Photodynamic Therapy.光动力疗法治疗光化性角化病中增殖和炎症生物标志物(Ki67、p53和COX-2)的靶向研究
Biomedicines. 2025 Jun 17;13(6):1487. doi: 10.3390/biomedicines13061487.
6
Dermoscopy and Pathological Correlation in Different Grades of Actinic Keratosis and Squamous Cell Carcinoma.不同分级的光化性角化病和鳞状细胞癌的皮肤镜检查与病理相关性
Clin Cosmet Investig Dermatol. 2025 Jun 3;18:1359-1373. doi: 10.2147/CCID.S521416. eCollection 2025.
7
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.4% 5-氟尿嘧啶乳膏治疗光化性角化病引起的局部皮肤反应的管理:德尔菲共识
Dermatol Pract Concept. 2025 Apr 1;15(2):5787. doi: 10.5826/dpc.1502a5787.
8
Clinical and experimental aspects of tirbanibulin treatments.替尔泊肽治疗的临床与实验方面
Arch Dermatol Res. 2025 Mar 19;317(1):603. doi: 10.1007/s00403-025-04119-9.
9
Calcipotriol as a daylight photodynamic therapy enhancer: a case-control study.骨化三醇作为日光光动力疗法增强剂:一项病例对照研究。
Dermatol Reports. 2025 Feb 6;17(1). doi: 10.4081/dr.2024.10077. Epub 2024 Oct 1.
10
Molecular Biomarkers in Cutaneous Photodynamic Therapy: A Comprehensive Review.皮肤光动力疗法中的分子生物标志物:综述
Diagnostics (Basel). 2024 Dec 3;14(23):2724. doi: 10.3390/diagnostics14232724.